Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

NCT03004248 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
2691
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Revance Therapeutics, Inc.